Totient
Company

Last deal

Amount

Venture - Series Unknown

Stage

05.01.2021

Date

1

all rounds

date founded

Financing round

General

About Company
Totient uses AI and lymphoid structures to develop antibody therapeutics for cancer, autoimmune disease, infections, and viruses.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

founders

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company leverages machine learning and immunoinformatics technology to reconstruct antibodies from tissues affected by autoimmunity, infections, and cancer collected from patients experiencing exceptional immune responses, providing clinicians with antibody therapeutics to treat cancer and other autoimmune diseases.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Evaxion Biotech

Evaxion Biotech

Evaxion Biotech develops AI-based immunotherapies for cancer and infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Artificial Intelligence, Health Care

Location

Copenhagen, Denmark

total rounds

5

total raised

$92M
Celsius Therapeutics

Celsius Therapeutics

Cisces Therapeutics develops precision medicines for cancer and autoimmune disease patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

2

total raised

$148M
DynamiCure

DynamiCure

DynamiCure is a biotechnology company that develops therapeutic antibodies to treat cancer, autoimmune, and other diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Waltham, MA, USA
Monument Therapeutics

Monument Therapeutics

Monument Therapeutics develops drugs to treat serious central nervous system diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, UK

total rounds

3

total raised

$5.48M
M&A Details
1

Transaction name

Acquired by

Absci

announced date

14.06.2021

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 05.01.2021. Their latest investor CerraCap Ventures. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
CerraCap Ventures

CerraCap Ventures

CerraCap Ventures is a venture capital firm that invests in disruptive companies with potential to dominate global markets.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Costa Mesa, CA, USA

count Of Investments

28

count Of Exists

5
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Venture - Series Unknown
CerraCap Ventures

CerraCap Ventures

CerraCap Ventures is a venture capital firm that invests in disruptive companies with potential to dominate global markets.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Costa Mesa, CA, USA

count Of Investments

28

count Of Exists

5
Vikas Datt

Vikas Datt

Vikas Datt is a Managing Partner of CerraCap Ventures.

current job

CerraCap Ventures
CerraCap Ventures

People

Founders
1
Deniz Kural
Deniz Kural

Deniz Kural

current job

Absci
Absci

organization founded

2

Deniz Kural

Employee Profiles
4

Irina Glotova

R and d team lead

Kelley Curry

People operations manager

Deniz Kural

Deniz Kural

CEO & Founder

Activity

Recent News
0